Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in seed financing from Novo Holdings, Bioqube Ventures, and Korys, today ...

Blyth is the founder and former CEO of LIfT BioSciences, a company developing neutrophil-based immunotherapies designed to ...

Scientists are closer to understanding how an everyday painkiller can help our bodies fight cancer. The findings may offer a complementary mechanism for preventing the development and progression of ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system-a group of proteins that ...